Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011
Volume 51, Issue -, Pages 99-115Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010510-100512
Keywords
tetrac; nanoparticulate tetrac; integrin alpha v beta 3; cancer cell proliferation; angiogenesis; ion transport; protein trafficking; growth factors
Categories
Ask authors/readers for more resources
Plasma membrane integrin alpha nu beta 3 is a cell surface receptor for thyroid hormone at which nongenomic actions are initiated. L-thyroxine (T-4) and 3,3',5-triiodo-L-thyronine (T-3) promote ang-iogenesis and tumor cell proliferation via the receptor. Tetraiodothyroacetic acid (tetrac), a deaminated T-4 derivative, blocks the nongenomic proliferative and proangiogenic actions of T-4 and T-3. Acting at the integrin independently of T-4 and T-3, tetrac and a novel nanoparticulate formulation of tetrac that acts exclusively at the cell surface have oncologically desirable antiproliferative actions on multiple tumor cell survival pathway genes. These agents also block the angiogenic activity of vascular growth factors. Volume and vascular support ofxenografts of human pancreatic, kidney, lung, and breast cancers are downregulated by tetrac formulations. The integrin alpha nu beta 3 receptor site for thyroid hormone selectively regulates signal transduction pathways and distinguishes between unmodified tetrac and the nanoparticulate formulation. The receptor also mediates nongenomic thyroid hormone effects on plasma membrane ion transporters and on intracellular protein trafficking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available